Drugs / Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody
Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07648069 | Sep 2024 → Dec 2026 expected | osteosarcoma, soft tissue sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07648069 ↗ |
| Modality | Cell therapy | “Tumor-Specific Lymphocyte Infusion: Throughout the treatment course, each subject receives tumor-specific lymphocyte infusions.” NCT07648069 ↗ |